World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
33012
World Ranking
13517
National Ranking
6874

Overview

Franco M. Muggia was affiliated with New York University in the United States. Their academic work primarily focused on the field of Medicine, with specific contributions to Oncology and related subfields such as Reproductive Medicine, Pulmonary and Respiratory Medicine, Molecular Biology, and Epidemiology.

The research topics covered by Muggia included ovarian cancer diagnosis and treatment, endometrial and cervical cancer treatments, BRCA gene mutations in cancer, cancer immunotherapy and biomarkers, pancreatic and hepatic oncology research, PARP inhibition in cancer therapy, and cancer risks and factors.

Among their recent papers were:

  • "Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up" (2020, Cancer Chemotherapy and Pharmacology)
  • "History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications" (2021, Cancer Drug Resistance)
  • "Temporal trends of subsequent breast cancer among women with ovarian cancer: a population-based study" (2020, Archives of Gynecology and Obstetrics)
  • "Breast radiation-associated secondary malignancies: A review" (2023, Clinical Surgical Oncology)
  • "Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer" (2021, ONCOLOGY)

Frequent co-authors in their work included:

  • Genitourinary Cancer
  • Julie Vose
  • Howard S. Höchster
  • Robert A. Figlin
  • Tanios Bekaii-Saab

Muggia published regularly in several venues, with the most frequent being:

  • ONCOLOGY
  • SSRN Electronic Journal
  • Gynecologic Oncology
  • Current Problems in Cancer Case Reports
  • Cancer Chemotherapy and Pharmacology

Best Publications

  • Risk factors for doxorubicin-induced congestive heart failure.

    Von Hoff Dd;Layard Mw;Basa P;Davis Hl

  • Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

    William E. Winter;G. Larry Maxwell;Chunqiao Tian;Jay W. Carlson

  • Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study

    Franco M. Muggia;Patricia S. Braly;Mark F. Brady;Gregory Sutton

  • Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

    F M Muggia;J D Hainsworth;S Jeffers;P Miller

  • The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group.

    N Petrelli;H O Douglass;L Herrera;D Russell

  • Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2

    T. Safra;F. Muggia;S. Jeffers;D. D. Tsao-Wei

  • Toxic effects of cis-dichlorodiammineplatinum(II) in man.

    Von Hoff Dd;Schilsky R;Reichert Cm;Reddick Rl

  • Cis-diamminedichloroplatinum (II): A New Anticancer Drug

    Rozencweig M;von Hoff Dd;Slavik M;Muggia Fm

  • Daunomycin-induced cardiotoxicity in children and adults: A review of 110 cases

    Daniel D. Von Hoff;Marcel Rozencweig;Maxwell Layard;Milan Slavik

  • Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

    Beatrice Uziely;Susan Jeffers;Rut Isacson;Kimberlea Kutsch

  • Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions

    Asher Chanan-Khan;J. Szebeni;S. Savay;L. Liebes

  • Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.

    C G Leichman;T R Fleming;F M Muggia;C M Tangen

  • Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.

    James L. Speyer;Michael D. Green;Elissa Kramer;Mariano Rey

  • Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

    Bradley J. Monk;Thomas J. Herzog;Stanley B. Kaye;Carolyn N. Krasner

  • Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

    William E. Winter;G. Larry Maxwell;Chunqiao Tian;Michael J. Sundborg

  • Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer.

    Williams Sd;Stablein Dm;Einhorn Lh;Muggia Fm

  • Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention.

    Janos Szebeni;Franco Muggia;Alberto Gabizon;Yechezkel Barenholz

  • The Modulation of Fluorouracil With Leucovorin in Metastatic Colorectal Carcinoma A Prospective Randomized Phase III Trial

    Nicholas Petrelli;Harold O. Douglass;Lemuel Herrera;David Russell

  • Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.

    Yi He Ling;Leonard Liebes;Jian Dong Jiang;James F. Holland

  • Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.

    S. Demaria;M. D. Volm;R. L. Shapiro;H. T. Yee

Frequent Co-Authors

Howard S. Hochster
Howard S. Hochster Yale University
Silvia C. Formenti
Silvia C. Formenti Cornell University
Daniel D. Von Hoff
Daniel D. Von Hoff Translational Genomics Research Institute
Sylvia Adams
Sylvia Adams New York University
Joseph A. Sparano
Joseph A. Sparano Albert Einstein College of Medicine
Alberto Gabizon
Alberto Gabizon Shaare Zedek Medical Center
Sridhar Mani
Sridhar Mani Albert Einstein College of Medicine
Susan Groshen
Susan Groshen University of Southern California
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Martine Piccart
Martine Piccart Université Libre de Bruxelles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in medicine but seeking alternative or accelerated routes, exploring online healthcare degrees can expand your options. Many programs now offer the flexibility and convenience to balance studies with personal and professional commitments.

Aspiring nurse leaders can benefit from the shortest dnp program options, providing a faster pathway to advanced clinical roles. Those looking for the quickest entry into nursing may consider a 9 month lpn program, which opens doors to practical nursing opportunities in less than a year.

For individuals interested in mental health, pursuing a fast track mental health nursing degree can lead to in-demand roles as a nurse practitioner specializing in psychiatric care. Alternatively, if you’re drawn to healthcare leadership, healthcare administration degrees offer a route to management and administrative positions within the medical field.

With a wide range of fast, flexible, and affordable online programs, you can tailor your medical career pathway to meet your goals and lifestyle.

Best Scientists Citing Franco M. Muggia

Recently Published Articles